(redirected from Blast count)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for leukemia

Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
(There are anecdotal reports that some physicians are handicapping themselves by not following the guidelines to do a 500-cell blast count. This may be because some pathologists are improperly trained, or the specimen may be of poor quality, or there is insufficient sample to enumerate 500 cells.)
Three Ph+ MDS patients developed isolated refractory anemia, normal platelets, low blast count, and more favorable outcome.
Between patients with MDS and a low BM blast count and patients with AA, only methylation levels ( P = 0.040, [Table 4] and [Figure 2]) of the ID4 gene had apparent differences, whereas ID4 gene methylation positivity rates did not ( P = 0.076, [Table 4] and [Figure 2]).
A study investigated 805 AML patients aged 20 93 years and found that the NPM1 mutations are associated with high WBC and blast count in 80 89% of AML patients.30 It is concluded from this study that NPM1 mutat-ion is not very common in AML patients in Pakistani population.
This analysis showed that neither sex and age nor WBC count, absolute blast count, hemoglobin level, platelet count, prothrombin time, and partial thromboplastin time were significantly related to prognosis in the study population.
Such an anti-leukemic action consisted in a median decrease by 53% (range 37%-99%) of peripheral blast count in 7 patients, and by 10% (range 6%-60%) of BM blasts in 4.
According to the European LeukemiaNet (ELN) recommendations, BC is defined using the threshold blast count in the peripheral blood or bone marrow at 30% [7].
investigated the effect of the ten-eleven translocation 2(TET2) gene mutations on AZA's efficacy in 86 MDS or low blast count AML patients and reported that the presence of a TET2 mutation predicted a higher response rate to AZA than the presence of wildtype TET2 did.
Most of patients carrying FLT3 gene mutation have a 50% decrease in the peripheral blast count, along with inhibition of receptor autophosphorylation.
An overall response rate (ORR) as determined by CR, CRi, partial remission, and bone marrow blast count normalization without blood count recovery was reported by investigators in 20 of 56 subjects for an ORR of 36 percent, with 12 of 56 subjects (21 percent) experiencing a CR or CRi.
During transformation to acute leukemia, the blast count increases to 20-30%.
Haferlach et al (16) proposed reclassification of inv(3)/t(3;3)-containing AML and MDS as AML with inv(3)/t(3;3) irrespective of blast count, based on clinicopathologic and molecular studies.